Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03581123
Other study ID # CSH-2018-26524
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date November 1, 2018
Est. completion date June 30, 2024

Study information

Verified date June 2024
Source University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study of adults with acute low back pain flare-up at risk of becoming chronic and disabling. The study tests how well spinal manipulation and guided selfcare work compared to standard medical care. The treatments last up to eight weeks and participants will be followed for one year.


Description:

The long-term goal is to reduce overall low back pain (LBP) burden by evaluating, first-line, non-drug treatment strategies that address the biological, psychological and social aspects of acute LBP and prevent transition to chronic back pain. The study will also assess barriers and facilitators that impact future implementation of the non-drug treatments into clinical practice. The US faces an unprecedented pain management crisis. LBP is the most common chronic pain condition in adults and one of the leading causes of disability worldwide. Guidelines have recommended non-drug treatments like spinal manipulation and behavioral and selfcare approaches for LBP for nearly a decade, yet uptake and adherence has been poor. Little is known about the role of these treatments in the secondary prevention of chronic LBP, especially for patients at risk of developing severe low back pain. Due to high societal costs, and side effects of commonly used drug treatments, including opioids, there is a critical need for research on how well non-drug treatments work for preventing serious chronic LBP.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1000
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age - Acute or sub-acute low back pain - Average low back pain severity =3 on the 0-10 numerical rating scale over 7 days - Medium or high risk for persistent disabling back pain according to the STarT Back screening tool - Ability to read and write fluently in English Exclusion Criteria: - Non-mechanical causes of low back pain - Contraindications to study treatments (e.g,. surgical fusion of lumbar spine) - Active management of current episode of low back pain by another healthcare provider - Serious co-morbid health condition that either requires medical attention or has a risk for general health decline over the next year - Pregnancy, current or planned during study period and nursing mothers - Inability or unwillingness to give written informed consent

Study Design


Intervention

Behavioral:
Supported-Self Management (SSM)
Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
Other:
Spinal Manipulation Therapy (SMT)
SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
Combination Product:
SMT + SSM
Combination Treatment
Drug:
Standard Medical Care (SMC)
Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota
United States University of Pittsburgh Pittsburgh Pennsylvania
United States University of Washington Seattle Washington

Sponsors (6)

Lead Sponsor Collaborator
University of Minnesota Duke University, Oregon Health and Science University, University of North Texas Health Science Center, University of Pittsburgh, University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Self-efficacy Using a 10-100 numerical rating scale (10=very uncertain, 100 = very certain), self-efficacy is measured with the 22-item Chronic Pain Self-Efficacy Scale adapted for acute/sub-acute pain. This is a psychosocial mediating measure. Baseline, 2, 6, 12 months
Other Catastrophizing Measured using the 13-item Pain Catastrophizing Scale; it uses a 5-item point scale (0=not at all, 4 all the time). This is a psychosocial mediating measure. Baseline, 2, 6, 12 months
Other Kinesiophobia Measured using the 11-item Tampa Scale for Kinesiophobia demonstrated to have internal consistency, responsiveness and validity similar to the original 17-item instrument. A four-item scale is used (strongly disagree to strongly agree). This is a psychosocial mediating measure. Baseline, 2, 6, 12 months
Other Coping Measured using an adapted version of the 28-item Brief Coping Orientation to Problems Experienced (COPE) instrument on a 4 point scale (I haven't been doing this at all to I've been doing this a lot). This is a psychosocial mediating measure. Baseline, 2, 6, 12 months
Primary Average pain intensity over one year post-randomization Measured using the 0-10 numerical rating scale (0=no LBP, 10=the worst LBP possible). Weekly from enrollment - 52 weeks
Primary Average disability over one year post-randomization Measured using the Roland-Morris Disability Questionnaire (RMDQ), a 24-item questionnaire that measures the degree to which a low back problem restricts daily activities. Measured monthly from enrollment - 52 weeks
Primary Prevention of chronic low back pain (LBP) that is impactful at 10-12 months follow-up Measured by the LBP impact scale which includes measures of pain intensity, pain interference, and physical function from the PROMIS-29 Profile v2.0. The scale ranges from 8 (least impact) to 50 (greatest impact). Months 10 -12
Secondary Recovery from acute/sub-acute low back pain Measured by the proportion of patients with scores of 0 on the 0-10 pain numeric rating scale (NRS) and a score of less than or equal to 2 on the Roland-Morris Disability Questionnaire (RMDQ), a 24-item questionnaire that measures the degree to which a low back problem restricts daily activities. 6 months
Secondary Patient-Reported Outcomes Measurement Information System (PROMIS-29) Includes pain interference with normal activities, physical function, anxiety, depression, fatigue, sleep disturbance and the ability to participate in social roles and activities. Measured monthly from enrollment - 52 weeks
Secondary Low Back Pain Frequency Participants report the number of days low back pain has been a problem in the past 7 days. Weekly from enrollment - 52 weeks
Secondary Healthcare Utilization Includes provider visits, emergency department visits, diagnostic imaging scans, hospitalizations, injections and surgical procedures. Measured monthly from enrollment - 52 weeks
Secondary Medication Use Over the counter and prescription medication use for low back pain including class and frequency by class. Measured monthly from enrollment - 52 weeks
Secondary Productivity loss Missed work and reduced productivity while at work will be assessed using questions from the Institute for Medical Technology Assessment's productivity cost questionnaire. Measured monthly from enrollment - 52 weeks
Secondary Risk factors for transitioning to chronic low back pain Measured using the STarT Back Screening Tool. Baseline, 2, 6, 12 months
Secondary Global Improvement Measured using a 9-point scale (completely recovered to vastly worse) Baseline, 2, 6, 12 months
Secondary Patient Satisfaction with Treatment Measured using a 7-point Likert scale (completely satisfied to completely dissatisfied) Baseline, 2, 6, 12 months
Secondary Healing Encounters and Attitudes Lists (HEAL) Includes patient-provider connection (7-item), healthcare environment (6-item), positive outlook (6-item) and treatment expectancy (6-item) from the HEAL measured on a 5-point scale (not at all to very much) Baseline, 2 weeks, and 1, 2, 6, 12 months
Secondary Intervention Barriers This qualitative assessment explores barriers to participation in the intervention using open ended questions in an electronic survey. Screening, baseline, 2, 6, 12 months
Secondary Intervention Facilitators This qualitative assessment explores facilitators to participation in the intervention using open ended questions in an electronic survey. Screening, baseline, 2, 6, 12 months
Secondary Covid 19 Impact Measured using the 7-item Pain Management Collaboratory (PMC) Coronavirus (COVID-19) Pandemic Measure Screening, baseline, 2, 6, 12 months
Secondary Telehealth Usability Questionnaire Participants' views of the remote intervention delivery platform will be assessed using items adapted from the Telehealth Usability Questionnaire Baseline, 1, 2 months
Secondary Adverse Events Any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline, appears to worsen. Measured during treatment and monthly from enrollment - 52 weeks
Secondary Prevention of chronic low back pain (LBP) Measured by the proportion of patients in each group meeting the definition by the NIH Task Force on Research Standards for Chronic LBP (i.e., ongoing LBP on =50% of days over past 6 months). 6, 12 Months
Secondary Timed Up and Go Test Measured by a blinded examiner, in seconds, the time taken by a person to stand up, walk a distance of 10 feet, turn, walk back to the chair and sit down again. Baseline and 2 months
Secondary Sit-to-stand Measured by a blinded examiner, in seconds, the amount of time a person requires to stand up and sit down from a chair 5 times without using their arms Baseline and 2 months
Secondary The Sock Test Measured by a blinded examiner on a scale from 0-3, with 0 being can easily grab the toes with the fingertips of both hands and 3 being can hardly, if at all, reach as far as to the malleoli. Baseline and 2 months
Secondary Chronic Interference with Daily Activities Assessed using "how often has low back pain interfered with your ability to do regular activities over the past 6 months?" on a 3-item scale (less than half the days in the past 6 months, at least half the days in the past 6 months, every day or nearly every day in the past 6 months). Baseline, 6 and 12 months
Secondary Visual Trajectory for Pain Assessed using 8 different diagrams describing back pain change over the last 12 months Baseline, 12 months
Secondary Quebec Task Force Measured by a blinded examiner who will classify the participant's spinal disorder as 0) no pain; 1) pain without radiation; 2) pain with radiation to the proximal extremity; 3) pain with radiation to the distal extremity; 4) pain with radiation to the extremity and neurologic signs. Baseline, 2 months
See also
  Status Clinical Trial Phase
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT03825549 - A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing N/A
Completed NCT05995912 - Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain Phase 2
Recruiting NCT05589246 - Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure N/A
Recruiting NCT05572190 - Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects Phase 1
Terminated NCT04716413 - Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment Phase 4
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Not yet recruiting NCT06317844 - Examination of Psychological and Physiological Pathways Linking Gratitude and Pain N/A
Withdrawn NCT02957097 - Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures Phase 4
Completed NCT02565342 - Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery Phase 4
Terminated NCT02599870 - Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures N/A
Completed NCT02984098 - 40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose Phase 4
Completed NCT02380989 - Integrative Ayurveda Healing Relieves Minor Sports Injury Pain Phase 2
Completed NCT02489630 - Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department Phase 4
Completed NCT03107338 - Preventive Treatment of Pain After Dental Implant Surgery Phase 4
Completed NCT02817477 - Intranasal Ketamine for Acute Traumatic Pain Phase 4